Press "Enter" to skip to content

Zoetis' Solensia Wins European Nod For Osteoarthritis Pain In Cats

  • Animal health company Zoetis Inc (NYSE: ZTS) received the European Commission’s marketing approval for Solensia (frunevetmab), an injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats.
  • Solensia targets Nerve Growth Factor (NGF), a key player in osteoarthritis pain. The veterinarian delivers the treatment as a monthly injection (under the skin).
  • In November last year, the Commission approved a similar product, Librela (bedinvetmab), for dogs.
  • Price Action: ZTS stock closed 4.7% lower at $160 on Friday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *